alisporivir for the treatment of hepatitis C virus infection

摘要

Patent Summary: "alisporivir for the treatment of hepatitis C virus infection". The present invention relates to the use of alisporivir (= debio-025 or deb025) in the treatment of an African-American patient infected with hepatitis c genotype 1 infection. alisporivir will be administered in an amount of approximately 400 to approximately 600 mg. twice daily, preferably in combination with other antiviral agents. In a preferred embodiment, the following dosing regimen is administered: pegylated interferon alfa 2a at a dose of 180 µg subcutaneously once weekly for 24 or 48 weeks in combination with ribavirin (rbv or copegus) administered as an oral dosage 800/1200 mg daily (weight based) for 24 or 48 weeks and 400 mg alisporivir (deb025) orally twice daily for 24 or 48 weeks.